Related Departments & Centers
Research in the Center is focused on basic research into immunological mechanisms with a long time goal of helping to design the next generation of vaccines. Investigators in the Center have research areas that focus on many areas of immunology, including T cell activation and differentiation, T cell memory and homing, MHC class II -restricted antigen presentation, T cell responses to pathogenic organisms and T cell-mediated autoimmunity.
The Center is a resource providing opportunities for training in advanced immunological techniques, access to standard operating procedures, sponsorship of human immunology seminar series, and discussion groups. The goals of the Rochester Human Immunology Center are accomplished through: (a) The Rochester Human Immunology Core laboratory, (b) Pilot Projects for innovative immunological research and technologies, (c) Human Immunology Seminar Series and special Symposia, and (d) Interdisciplinary Discussion groups.
The New York Influenza Center of Excellence (NYICE) is collaborative, interdisciplinary approach involving investigators in the fields of immunology, virology, biochemistry, medicine, pediatrics, statistics and bioinformatics that will address directly the issues of cross-protective immunity and virus adaptation to the mammalian host. Our goal is to provide a truly transforming approach to influenza research.
The University of Rochester (UR) HIV/AIDS Clinical Trials Unit (CTU), also known as the Rochester Victory Alliance (RVA), is one of the Clinical Research Sites (CRS) of the National Institute of Health (NIH). The UR HIV/AIDS CTU, part of the Infectious Disease Division, has been conducting HIV research since 1987. It is co-led by Drs. Michael Keefer and Stephen Dewhurst.
The UR HIV/AIDS CTU encompasses both the UR Adult HIV Therapeutic Strategies CRS and the UR Vaccines to Prevent HIV Infection CRS.
The Office of Technology Transfer is comprised of the teams who facilitate the protection of Intellectual Property and the commercialization—or transfer—of technologies resulting from the cutting-edge research being conducted by the world-class scientists, faculty, and staff here at the University of Rochester and the University of Rochester Medical Center.
The NIH Public Access policy mandates public access to the results of NIH funded research in order to advance science and improve human health. The policy applies to all peer-reviewed papers based on research funded by NIH that are accepted for publication on or after April 7, 2008. For more information, click the above link.
The goal of the University of Rochester Virtual Drug Discovery Center (UR VDDC) is to accelerate research by investigators at the University of Rochester who are working on new drug discovery.
This site is organized to provide assistance with each step during the drug discovery process, and to provide access to local expertise and investigators who can provide advice and assistance with drug development projects, at all stages.
The University of Rochester is home to the world's most comprehensive resource specializing in the use of the amphibian Xenopus laevis for biomedical and immunological research. Several genetically-defined inbred strains and clones are available for study. The facility also maintains and develops research tools such as transgenic animals, monoclonal antibodies, cell lines, DNA libraries and molecular probes.
Research Core Facilities
The Core Facilities provide services to all researchers at the University of Rochester School of Medicine and Dentistry. An Executive Oversight Committee provides the Senior Associate Dean of Basic Research with recommendations for overall core facility strategic planning and management.